Ciforadenant

DRUG3 trials

Sponsors

Corvus Pharmaceuticals, Inc., M.D. Anderson Cancer Center

Conditions

Metastatic Castration Resistant Prostate CancerMultiple MyelomaRenal Cell CancerRenal Cell Carcinoma

Phase 1

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

CompletedNCT02655822

Corvus Pharmaceuticals, Inc.Metastatic Castration Resistant Prostate Cancer, Renal Cell Cancer

Start: 2016-01-31End: 2021-07-31Updated: 2021-08-30

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT04280328

Corvus Pharmaceuticals, Inc.Multiple Myeloma

Start: 2020-02-20End: 2022-03-01Updated: 2022-03-11

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Active, not recruitingNCT05501054

M.D. Anderson Cancer CenterRenal Cell Carcinoma

Start: 2023-02-09End: 2026-11-01Updated: 2026-07-16

Related Papers

AVALIAÇÃO DE NOVOS TRATAMENTOS PARA TUMORES SÓLIDOS QUE TIVERAM COMO ALVO A VIA ADENOSINÉRGICA

Hematology Transfusion and Cell Therapy2023-10-01

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma.

2021-04-0913 citations

CD68+ tumor-associated myeloid cells as the target of adenosine-induced gene products and predictor of response to adenosine blockade with ciforadenant (cifo) in renal cell cancer (RCC).

Journal of Clinical Oncology2020-05-202 citations

Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-02-1929 citations

Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444

Annals of Oncology2018-10-018 citations

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.

Journal of Clinical Oncology2017-05-2044 citations